Skip to main content

Advertisement

SpringerLink
Log in

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and supportive medications. We now seek to understand how QoL and fatigue impacts survival in recurrent HGG. Using a prospective observational design, 237 patients with recurrent HGG and KPS ≥70 completed a self-administered questionnaire that evaluated QoL and fatigue. QoL was assessed with Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-Brain (FACT-Br) scales while fatigue was assessed using Functional Assessment of Chronic Illness Therapy (FACIT-F) scale. Cox proportional hazard models were utilized to evaluate the association between QoL and fatigue and survival. Seventy-three (31 %) subjects had recurrent WHO grade III gliomas and 164 (69 %) had recurrent WHO grade IV gliomas. Median follow-up analysis was 27.60 months. In univariate Cox analyses, the FACT-Br specific subscale (HR 0.88; CI 95 %, 0.77–1; p = 0.048) and FACIT-F (HR 0.82; CI 95 %, 0.68–0.99; p = 0.045) were both significant predictors of survival. Fatigue added prognostic information beyond that provided by KPS, age, sex, tumor grade, and number of prior progressions (HR 0.80; CI 95 %, 0.68–0.9; p = 0.031). A greater degree of fatigue was associated with poorer survival in recurrent HGG patients. In multivariable analyses, FACT-G and FACT-Br are not independent predictors of prognosis. Fatigue is a strong independent predictor of survival that provides incremental prognostic value to the traditional markers of prognosis in recurrent HGG. Pharmacological or non-pharmacological strategies to treat fatigue warrant investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342. doi:10.1007/978-1-60327-492-0_14

    Article  CAS  PubMed  Google Scholar 

  2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin oncol 17:2572–2578

    CAS  PubMed  Google Scholar 

  3. Kyritsis AP, Levin VA (2011) An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 67:971–983. doi:10.1007/s00280-011-1617-9

    Article  CAS  PubMed  Google Scholar 

  4. Wen PY, Brandes AA (2009) Treatment of recurrent high-grade gliomas. Curr Opin Neurol 22:657–664. doi:10.1097/WCO.0b013e32833229e3

    Article  CAS  PubMed  Google Scholar 

  5. Heimans JJ, Taphoorn MJ (2002) Impact of brain tumour treatment on quality of life. J Neurol 249:955–960. doi:10.1007/s00415-002-0839-5

    Article  PubMed  Google Scholar 

  6. Taphoorn MJ, Sizoo EM, Bottomley A (2010) Review on quality of life issues in patients with primary brain tumors. Oncologist 15:618–626. doi:10.1634/theoncologist.2009-0291

    Article  PubMed Central  PubMed  Google Scholar 

  7. Cheng JX, Liu BL, Zhang X, Lin W, Zhang YQ, Liu WP, Zhang JN, Lin H, Wang R, Yin H (2010) Health-related quality of life in glioma patients in China. BMC Cancer 10:305. doi:10.1186/1471-2407-10-305

    Article  PubMed Central  PubMed  Google Scholar 

  8. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 97:302–307. doi:10.1038/sj.bjc.6603876

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC (2005) A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 57:495–504 discussion 495-504 12

    Article  PubMed  Google Scholar 

  10. Giovagnoli AR, Silvani A, Colombo E, Boiardi A (2005) Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 76:562–568. doi:10.1136/jnnp.2004.036186

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871. doi:10.1016/S1470-2045(09)70200-1

    Article  PubMed  Google Scholar 

  12. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737. doi:10.1200/JCO.2007.11.1476

    Article  PubMed  Google Scholar 

  13. Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, Tang-Wai DF, Arusell RM, Clark MM, Buckner JC (2006) Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 76:283–291. doi:10.1007/s11060-005-7020-9

    Article  PubMed  Google Scholar 

  14. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650

    CAS  PubMed  Google Scholar 

  15. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.1200/JCO.2009.26.3541

    Article  PubMed  Google Scholar 

  16. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161

    Article  CAS  PubMed  Google Scholar 

  17. Van Belle S, Paridaens R, Evers G, Kerger J, Bron D, Foubert J, Ponnet G, Vander Steichel D, Heremans C, Rosillon D (2005) Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue. Support Care Cancer 13(4):246–254. doi:10.1007/s00520-004-0734-y

    Article  PubMed  Google Scholar 

  18. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43–46

    CAS  PubMed  Google Scholar 

  19. Cella D, Lai JS, Chang CH, Peterman A, Slavin M (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528–538. doi:10.1002/cncr.10245

    Article  PubMed  Google Scholar 

  20. Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW (2011) Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol 29:2918–2923. doi:10.1200/JCO.2011.34.9852

    Article  PubMed Central  PubMed  Google Scholar 

  21. Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102. doi:10.1186/1477-7525-7-102

    Article  PubMed Central  PubMed  Google Scholar 

  22. Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method. BMJ 310:170

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Sullivan PW, Nelson JB, Mulani PM, Sleep D (2006) Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 15:1297–1306. doi:10.1007/s11136-006-0003-2

    Article  PubMed  Google Scholar 

  24. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT (2007) Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat 105:209–219. doi:10.1007/s10549-006-9447-x

    Article  PubMed  Google Scholar 

  25. Brown DJ, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103:377–382. doi:10.1002/cncr.20777

    Article  PubMed  Google Scholar 

  26. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(353–360):14

    Google Scholar 

  27. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology 14:151–161

    CAS  PubMed  Google Scholar 

  28. Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91:822–828. doi:10.1038/sj.bjc.6602012

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Piper BF, Cella D (2010) Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Cancer Netw: JNCCN 8:958–966

    PubMed  Google Scholar 

  30. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O’Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI (2010) Cancer-related fatigue. J Natl Compr Cancer Netw: JNCCN 8:904–931

    PubMed  Google Scholar 

  31. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology 12:369–377

    CAS  PubMed  Google Scholar 

  32. Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447. doi:10.1176/appi.psy.50.5.440

    Article  PubMed Central  PubMed  Google Scholar 

  33. Morton A, King D (2003) Fatigue and endocrine disorders: causes and comorbidities. Aust Fam Physician 32:895–900

    PubMed  Google Scholar 

  34. Duffner PK (2004) Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10:293–310. doi:10.1097/01.nrl.0000144287.35993.96

    Article  PubMed  Google Scholar 

  35. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P (1993) Hypothalamic-pituitary dysfunction after radiation for brain tumors. New Engl J Med 328:87–94. doi:10.1056/NEJM199301143280203

    Article  CAS  PubMed  Google Scholar 

  36. Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Cancer Netw: JNCCN 6:448–455

    PubMed  Google Scholar 

  37. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071. doi:10.1016/j.ncl.2007.07.015

    Article  PubMed  Google Scholar 

  38. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M (2011) Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 29:4430–4435. doi:10.1200/JCO.2011.35.5750

    Article  PubMed  Google Scholar 

  39. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH (2010) Risk factors for fatigue severity in primary brain tumor patients. Cancer 116:2707–2715. doi:10.1002/cncr.25018

    PubMed  Google Scholar 

  40. Pruitt AA (2011) Medical management of patients with brain tumors. Curr Treat Options Neurol 13:413–426. doi:10.1007/s11940-011-0132-y

    Article  PubMed  Google Scholar 

  41. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS (2011) A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. doi:10.1007/s11060-011-0723-1

    Google Scholar 

  42. Meyers CA, Weitzner MA, Valentine AD, Levin VA (1998) Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522–2527

    CAS  PubMed  Google Scholar 

  43. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG (2007) A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 69:1496–1501. doi:10.1016/j.ijrobp.2007.05.076

    Article  CAS  PubMed  Google Scholar 

  44. Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, Haykowsky M (2011) Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist 16:112–120. doi:10.1634/theoncologist.2010-0197

    Article  PubMed Central  PubMed  Google Scholar 

  45. Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309. doi:10.1200/JCO.2005.04.6086

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA

    Katherine B. Peters & Annick Desjardins

  2. Department of Pediatrics, Duke University Medical Center, Durham, NC, 27710, USA

    Miranda J. West

  3. Department of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA

    Whitney E. Hornsby & Emily Waner

  4. Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA

    April D. Coan

  5. Department of Biostatistics, Duke University Medical Center, Durham, NC, 27710, USA

    Frances McSherry & James E. Herndon II

  6. Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA

    Henry S. Friedman

  7. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA

    Lee W. Jones

Authors
  1. Katherine B. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miranda J. West
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Whitney E. Hornsby
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily Waner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. April D. Coan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frances McSherry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James E. Herndon II
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henry S. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Annick Desjardins
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lee W. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine B. Peters.

Additional information

Previous patient demographics have been publshed in Ruden E et al. [20].

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peters, K.B., West, M.J., Hornsby, W.E. et al. Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. J Neurooncol 120, 499–506 (2014). https://doi.org/10.1007/s11060-014-1574-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1574-3

Keywords

Search

Navigation